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Abstract 50 
Neuromedin U (NMU) is a highly conserved endogenous peptide that is involved in a wide range of 51 
physiological processes such as regulation of feeding behavior, the stress response and nociception. 52 
The major limitation to use NMU as a therapeutic is its short half-life. Here, we describe the 53 
development of a set of novel NMU-analogs based on NMU-8, by introducing unnatural amino acids 54 
into the native sequence. This approach shows that it is possible to generate molecules with increased 55 
potency and improved plasma stability without major changes of the peptidic nature or the 56 
introduction of large conjugates. When compared to the native NMU-8 peptide, compounds 16, 18 and 57 
20 have potent agonist activity and affinity for both NMU receptors. Selectivity towards NMUR1 was 58 
observed when the Phe residue in position 4 was modified, whereas higher potencies at NMUR2 were 59 
found when substitutions of the Pro residue in position 6 were executed. To study the effect of the 60 
modifications on the proteolytic stability of the molecules, an in vitro stability assay in human plasma 61 
at 37 °C was performed. All analyzed analogs possessed an increased resistance against enzymatic 62 
degradation in human plasma resulting in half-lifes from 4 min for NMU-8, up to more than 23 h for 63 
compound 42.  64 
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Graphical abstract 65 
 66 
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Highlights 67 
• Insertion of unnatural amino acids in NMU-8 leads to stable and selective ligands 68 
• Potent NMUR ligands can be found by substitution of the Tyr1 residue of NMU-8 69 
• NMUR1 selectivity can be achieved by modification of Phe in position 4 70 
• Replacement of the Pro6 residue shifts the selectivity towards NMUR2  71 
• Biodegradation profiles are studied in human plasma 72 
Keywords 73 
Neuromedin U (NMU), NMU-8, Neuromedin U receptor agonists, plasma stability 74 
Abbreviations 75 
1’Nal, 1’-naphtylalanine; 2’Nal, 2’-naphtylalanine; 7-OH-Tic, 7-hydroxy-L-1,2,3,4-76 
tetrahydroisoquinoline-3-carboxylic acid; ACN, acetonitrile; AUC, area under the curve; CNS, central 77 
nervous system; Dap, α,β-diaminopropionic acid; DCM, dichloromethane; DIC, diisopropyl 78 
carbodiimide; DIPEA, N,N-diisopropylethylamine; DMEM, Dulbecco’s Modified Eagle Medium; 79 
DMF, dimethylformamide; DMSO, dimethyl sulfoxide; Dmt, 2’,6’-dimethyltyrosine; EC50, half 80 
maximal effective concentration; Emax, maximal effect; FA, formic acid; Fmoc, 9-81 
fluorenylmethyloxycarbonyl; GPCR, G protein-coupled receptor; HBSS, Hanks Balanced Salt 82 
Solution; HEK, human embryonic kidney; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 83 
acid; HOBt, 1-hydroxybenzotriazole; HPLC, high performance liquid chromatography; IC50, half 84 
maximal inhibitory concentration; IP3, inositol triphosphate; MS, mass spectrometry; NMU, 85 
neuromedin U; NMUR, neuromedin U receptor; Oic, octahydroindole carboxylic acid; PEG, 86 
polyethylene glycol; rt, room temperature; SAR, structure activity relationship; sc, subcutaneous; 87 
SPA, scintillation proximity assay; SPPS, solid phase peptide synthesis; TBTU, 2-(1H-Benzotriazole-88 
1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate; TES, triethylsilane; TFA, trifluoroacetic acid; Tic, 89 
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.   90 
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Introduction 91 
Neuromedin U (NMU) was initially discovered in porcine spine by Minamino et al. in 1985 and 92 
named after its uterus stimulating activity [1]. Following its discovery, NMU was isolated from 93 
different species and found to occur in two active forms, a 23 or 25 amino acid long peptide and a 94 
truncated version of 8 or 9 amino acids, which is generated by cleavage at the C-terminus of the longer 95 
NMU sequence.  96 
 97 
Figure 1. Human, rat and mouse NMU. The residues marked in red and the C-terminal amidation are 98 
entirely conserved in mammalian species. The sequences are elongated with asterisks to align similar 99 
amino acid residues. [Double column Figure]  100 
A remarkable homology, in particular at the C-terminus, can be observed between the different 101 
isoforms of NMU in different species (Figure 1). Across all mammals the C-terminal amidated 102 
heptapeptide (Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2) is entirely conserved, which implies that this is an 103 
important part for its biological functioning [2, 3]. The NMU peptide is widely distributed in the body, 104 
both in the periphery and centrally, with the highest levels in the gastrointestinal tract and the 105 
hypothalamus and anterior pituitary gland of the brain [4-6]. NMU plays a role in different 106 
physiological processes such as smooth muscle contraction, blood pressure, regulation of the stress 107 
response, feeding and energy homeostasis, nociception and immune regulation [3]. It exerts its effects 108 
via two G protein-coupled receptors (GPCRs), NMUR1 and NMUR2. NMUR1 is particularly found in 109 
the periphery, whereas NMUR2 is mainly expressed in the central nervous system (CNS) [2, 3]. Since 110 
NMU interacts with the regulation of feeding behavior, exerting anorexigenic effects [7], there has 111 
recently been a lot of interest in the development of NMUR agonists for the treatment of diabetes and 112 
obesity, major health concerns for modern society [8, 9]. Moreover, NMU-deficient mice become 113 
obese with age and these NMU-/- mice are characterized by an increased body weight and adiposity, 114 
hyperphagia, and a decrease in locomotor activity and energy expenditure [10]. Conversely, mice 115 
overexpressing NMU are leaner than wild type animals and are characterized by hypophagia and an 116 
improved glucose tolerance [11].  117 
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 118 
Figure 2. Structure and sequence of NMU-8 [single column Figure] 119 
Several novel NMU-analogs have been synthesized over the past years. Like many other naturally 120 
occurring peptides, NMU has a typical short half-life of less than 5 min after subcutaneous (sc) 121 
injection [12]. To unveil critical amino acid residues and to develop potent peptidergic NMU-analogs 122 
with improved stability, Hashimoto et al. performed a first structure activity relationship (SAR) study 123 
on isolated chicken smooth muscle preparations with the NMU-8 peptide (Figure 2). D-amino acid 124 
substitutions revealed two non-competitive antagonists, namely [D-Pro6]-NMU-8 and [D-Leu3,D-125 
Pro6]-NMU-8 [13]. The introduction of acyl groups, such as an acetyl, benzoyl and propionyl moiety, 126 
to the N-terminus led to the discovery of peptides with an increased contractile activity [14]. 127 
Additional SAR studies on the peripheral avian NMU receptors [15-17] and the synthesis of selective 128 
hexapeptide agonists [18-20] revealed the importance of the C-terminal Pro-Arg-Asn-NH2 segment for 129 
activation of both receptors.  130 
Selectivity towards NMUR1 could be obtained by introducing Trp or 2’naphtylalanine (2’Nal) at 131 
position 3 (Leu in the natural sequence) and selectivity towards NMUR2 was reported when Arg5 was 132 
replaced by an α,β-diaminopropionic acid (Dap) residue. Further elaboration of this SAR study 133 
resulted in a NMUR2 selective hexapeptide agonist, namely 3-cyclohexylpropionyl-Leu-Leu-Dap-134 
Pro-Arg-Asn-NH2 [18]. Although a selective agonist of NMUR1 was described by Takayama et al. as 135 
well, this analog (i.e. 2-thienylacetyl-Trp-Phe(4-F)-Arg-Pro-Arg-Asn-NH2) still activated NMUR2 to 136 
an important extent [19]. A further finetuning of this molecule led to the discovery of a potent 137 
NMUR1 selective hexapeptide agonist by replacing Phe(4-F) with a (αMe)Trp [20]. 138 
Additionally, other novel analogs based on the truncated form of NMU, such as small lipidated NMU-139 
analogs [21] and PEGylated NMU-8 [22], were already described to have potent anorectic and anti-140 
obesity effects. Several molecules based on the long version of NMU were synthesized as well, 141 
including a NMU-25 conjugate with human serum albumin [23], a PEGylated NMU-25 derivative 142 
[24] and lipidated NMU-25 analogs [25]. These molecules were reported to display potent and long-143 
lasting effects on food intake when peripherally administered in mice. Altogether, NMU holds a great 144 
therapeutic promise. 145 
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In this study, we describe the synthesis and in vitro evaluation of a series of peptidergic NMU ligands, 146 
based on the naturally occurring NMU-8, as lead molecule. Although not naturally occurring in 147 
human, NMU-8 was used as a lead since this peptide has the same C-terminal amino acid sequence as 148 
human (h) NMU-25, and acts as a full agonist on the hNMURs without a loss in potency [26]. A first 149 
set of analogs consisted of peptides with modifications described in literature on one hand and new 150 
peptidergic ligands on the other hand. This approach allowed to verify if the previous reported activity 151 
profiles on chicken crop smooth muscle preparations are similar when analyzed in the commonly used 152 
human embryonic kidney 293 (HEK293) cell line. In a second set of NMU-analogs, steric bulk, 153 
conformational constraints and ‘peptoid’ residues were introduced with the aim of developing peptides 154 
with NMUR subtype selectivity, improved pharmacokinetics and enhanced proteolytic stability. The 155 
effect of the introduced modifications on the affinity and activity at NMUR1 and NMUR2 was 156 
evaluated on HEK293 cells transiently expressing one of these receptors. The effect of some key 157 
modifications on the half-life of the analogs was determined in an in vitro stability assay with human 158 
plasma.   159 
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Material and Methods 160 
Chemicals 161 
2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU), N,N-162 
diisopropylethylamine (DIPEA), dimethylformamide (DMF), 4-methyl-piperidine, dichloromethane 163 
(DCM), 1-hydroxybenzotriazole (HOBt), diisopropylcarbodiimide (DIC), bromoacetic acid, dimethyl 164 
sulfoxide (DMSO), triethylsilane (TES), acetonitrile (ACN), fetal bovine serum and poly-D-lysine 165 
were obtained from Sigma Aldrich (Saint Louis, Missouri, USA). Acetic anhydride, diethylether and 166 
Pd/BaSO4 were purchased from Millipore, Merck (Darmstadt, Germany). Trifluoroacetic acid (TFA) 167 
was obtained from Fluorochem Ltd (Hadfield, UK). All amino acids were purchased from Iris Biotech 168 
GmbH (Marktredwitz, Germany). Tritium gas was from Technobexport (Moscow, Russia). 169 
Dulbecco’s Modified Eagle Medium (DMEM) with GlutaMAXTM, Opti-MEM with GlutaMAXTM and 170 
Hanks Balanced Salt Solution (HBSS) were products from Gibco, Life Technologies (Carlsbad, 171 
California, USA). Lipofectamine 2000 was from Invitrogen (Carlsbad, California, USA). Myo-[2-172 
3H(N)]inositol, Scintillation Proximity Assay (SPA)-yttrium silicate beads solution and Micro-Scint 20 173 
were purchased from Perkin Elmer (Waltham, Massachusetts, USA). Human plasma was obtained 174 
from the Belgian Red Cross (Leuven, Belgium). Formic acid (FA) was purchased from J.T. Baker 175 
(Center Valley, Pennsylvania, USA). 176 
General 177 
Analytical high performance liquid chromatography (HPLC) was carried out on an Agilent 1100 178 
HPLC system with ChemStation for LC 3D software (Discovery® BIO Wide Pore RP C18 column, 15 179 
cm × 2.1 mm, 3 µm from Supelco, Bellefonte, Pennsylvania, USA). Gradient elution took place using 180 
water with 0.1 % TFA and ACN with 0.1 % TFA as mobile phases. UV-detection was carried out at 181 
215 nm. Peptides were purified using a preparative HPLC apparatus from Gilson with Unipoint 182 
software package (Discovery® BIO Wide Pore C18 column, 25 cm × 21.2 mm, 5 µm from Supelco). 183 
The same mobile phases were used as for analytical HPLC and UV detection was carried out at 215 184 
nm as well. Mass spectrometry (MS) was performed on a Micromass Q-Tof micro spectrometer with 185 
electrospray ionization. Data collection and spectrum analysis were executed with Masslynx software. 186 
Peptide synthesis 187 
All peptides were manually synthesized by the 9-fluorenylmethyloxycarbonyl (Fmoc)-based solid 188 
phase peptide synthesis (SPPS) on Rink Amide AM resin (ChemImpex, 0.45 – 0.60 mmol g−1). For 189 
standard couplings, Fmoc-protected amino acids (3 equiv) were sequentially coupled with TBTU (3 190 
equiv) and DIPEA (9 equiv) for 1 h at room temperature (rt) in DMF. Fmoc deprotection was carried 191 
out in a two-step manner (5 min and 15 min) by treating the resin with a 20% (v/v) 4-methyl-192 
piperidine solution in DMF. After each coupling and Fmoc deprotection, the resin was washed 193 
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thoroughly with DMF (3x) and DCM (3x). Amino acids containing an unprotected phenol in their side 194 
chain [7-hydroxy-L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (7-OH-Tic) and 2’,6’-195 
dimethyltyrosine (Dmt)] were coupled for 45 min at rt using a 2-fold excess of the Fmoc-protected 196 
amino acid, HOBt (2 equiv) and DIC (2 equiv) in DMF. The same coupling conditions were in that 197 
case used until completion of the peptide sequence, as well as when hydroxyl-containing ‘peptoid’ 198 
residues were present in the sequence. 199 
N-substituted glycines were prepared on the solid support using the following method: after Fmoc 200 
deprotection, bromoacetylation of the amine was performed by adding 20 equiv of bromoacetic acid 201 
and 25 equiv of DIC in DMF for 1 h. This mixture was filtered off and the resin was washed as 202 
described above. Next, 20 equiv of the primary amine was added to the resin in DMSO and mixed for 203 
1 h to introduce the side chain [27]. After insertion of the side chain, further peptide assembly was 204 
continued as described above.  205 
Acetylation of the N-terminus was performed with acetic anhydride (10 equiv) and DIPEA (5 equiv) 206 
in DMF for 1 h. When unprotected reactive side chains were present, the acetylation was executed for 207 
30 min with half of the standard amounts, more precisely 5 equiv of acetic anhydride and 2.5 equiv of 208 
DIPEA. Cleavage from the resin and side chain deprotection were performed with TFA/TES/water 209 
(95/2.5/2.5 v/v/v) at rt for 3 h. The resulting cleavage mixture was evaporated to remove the TFA. The 210 
residue was next added to cold diethylether and centrifuged for 3 min at 3000 rpm. The precipitate was 211 
redissolved in a mixture of water and ACN (1/1 v/v) and lyophilized. Finally, the crude peptide was 212 
purified by preparative reversed phase HPLC (RP-HPLC) and lyophilized again. The structure of the 213 
pure product was confirmed by high-resolution MS (HRMS). The purity of all peptides was more than 214 
95% according to HPLC analysis. 215 
Tritium labeling of NMU-8 216 
Iodogen (0.92 µmol) was dissolved in 200 µL CH2Cl2 and the solution was evaporated to dryness 217 
under nitrogen in a reaction vial. NMU-8 (0.69 µmol) was dissolved in 1 mL of 50 mM Na2HPO4 218 
buffer pH 7.0 and the solution was added to the freshly prepared iodogen film. 2 µmol of NaI in 50 219 
mM Na2HPO4 buffer pH 7.0 was added and the mixture was stirred at rt for 1 min. Next, the solution 220 
was removed and mixed with 125 µL of 2 mg/mL Na2S2O5 in 50 mM Na2HPO4 buffer pH 7.0. The 221 
resulting solution was purified by RP-HPLC (Vydac 218TP54 column (250 x 4.6 mm, 5 µm) with a 222 
yield of 0.8 mg (73%)). For the tritium labeling, [Tyr1(3’-I)]-NMU-8 was dissolved in 200 µL DMF 223 
containing 1 µL of trimethylamine and the solution was reacted with 3H2 gas in the presence of 224 
PdO/BaSO4 (10% Pd) catalyst for 2 h at room temperature. The catalyst was filtered off and the labile 225 
tritium atoms were removed with repeated evaporation from EtOH/water (1/1 v/v) solution. Finally, 226 
the tritium labeled peptide was purified by HPLC (Phenomenex Luna C18(2) column, 5 µm, Torrance, 227 
California, USA). The molar activity was determined with HPLC area under the curve (AUC) 228 
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measurement using a calibration curve of NMU-8, and was found to be 1.09 Tbq/mmol (29.4 229 
Ci/mmol). 230 
In vitro functional assay on NMUR1 and NMUR2 231 
An inositol triphosphate (IP3) SPA analysis was performed to study the functional activity of the novel 232 
NMU-analogs at NMUR1 and NMUR2, since both receptors are described to signal mainly through 233 
the Gαq/11 pathway [25, 28]. HEK293 cell cultures were maintained in DMEM with GlutaMAXTM, 234 
supplemented with 10 % fetal bovine serum, 180 units/mL of penicillin and 45 µg/mL streptomycin. 235 
These cultures were incubated at 37 °C with 10 % CO2 and a relative humidity of 95 %. The day prior 236 
to the transfection with NMUR1, HEK293 cells were seeded in transparent 96-well plates coated with 237 
poly-D-lysine with a density of 30 000 cells/well. Transfection was carried out by incubating the 238 
plates for 5 h with 10 ng of hNMUR1 plasmid and 0.15 µL of lipofectamine 2000 in Opti-MEM with 239 
GlutaMAXTM. An empty vector (pCMV) transfection was carried out as a negative control. One day 240 
after transfection, the HEK293 cells were incubated for 24 h with 5 µCi of myo-[2-3H(N)]inositol per 241 
well in DMEM with GlutaMAXTM. For the preparation of HEK293 cells expressing NMUR2, the 242 
calcium phosphate transfection method was used. The day prior to the transfection, HEK293 cells 243 
were inoculated in T175 flasks with a density of 6 000 000 cells in 20 mL of culture medium. The 244 
transfection mixture was prepared by dripping a solution of the hNMUR2 plasmid and calcium 245 
chloride (2 M) in tris-EDTA-buffer into 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 246 
buffered saline (2x). This mixture was slowly added onto the cells while holding the flask vertically. 247 
The HEK293 cells were incubated for 5 h at 37 °C. As a negative control, an empty vector (pcDNA) 248 
transfection was carried out. The day after the transfection, cells were seeded out in transparent 96-249 
well plates coated with poly-D-lysine with a density of 35 000 cells/well using culture medium 250 
supplemented with 5 µL myo-[2-3H(N)]inositol per mL. On the assay day, the plates were washed 251 
twice with HBSS and incubated during 30 min at 37 °C with 100 µL/well of 10 mM lithium chloride 252 
in HBSS. To each well, 5  µCi of a peptide solution was added and incubated for 60 min at 37 °C. 253 
After peptide stimulation, the cells were lysed with 50 µL/well of 10 mM FA on ice for 30 min. 35 µL 254 
of the lysates was transferred into white 96-well plates and 80 µL of SPA-yttrium silicate beads 255 
solution was added to each well. The plates were sealed and shaken for 30 min. After spinning the 256 
plates for 5 min at 1500 rpm, the decay was measured, with a delay of 8 h, during 2 min/well with the 257 
Topcount (Packard Instrument Company, Meriden, Connecticut, USA). Each NMU analog was tested 258 
in a concentration range of 10-5 to 10-11 M in at least 3 independent experiments using triplicates. 259 
Competitive binding assay at NMUR1 and NMUR2 260 
To evaluate the affinity of the novel NMU-analogs for the NMURs, a competitive binding study was 261 
performed with [3H]-NMU-8 as radioligand. Transfection of the HEK293 cells with hNMUR1 or 262 
hNMUR2 was carried out in the same ways as describe above for the functional assay with the only 263 
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difference that myo-[2-3H(N)]inositol was not added to the medium. On the assay day, the plates were 264 
washed twice with binding buffer (50 mM HEPES buffer at pH 7.5 supplemented with 5 g/L bovine 265 
serum albumin). 50 µL per well of binding buffer was added and incubated at 4 °C during 15 min. To 266 
each well, 5 µL of the peptide dilution series was added, followed by 50 µL of [3H]-NMU-8 (250 cpm, 267 
0.23 nM). The plates were incubated for 3 h at 4 °C. Afterwards, the plates were washed twice with 268 
binding buffer and 100 µL of Micro-Scint 20 was added to each well. The plates were sealed and 269 
gently shaken for 30 min. The decay was measured with the Topcount instrument. Each NMU analog 270 
was tested in a concentration range of 10-5 to 10-11 M in at least 3 independent experiments using 271 
triplicates. 272 
In vitro plasma stability 273 
An in vitro stability assay in human plasma was performed to study the effect of the introduced 274 
modifications on enzymatic stability. Prior to the stability test, selectivity of the assay, stability of the 275 
compound in the injection solvent, linearity, accuracy and precision of the method were investigated. 276 
The NMU analogs were dissolved in water and consecutive dilutions were prepared with the same 277 
solvent. An aqueous peptide solution was spiked in human plasma (10/90 v/v), which was incubated at 278 
37 °C, with a final plasma concentration of 112 µM.  Samples were taken at selected time points, 279 
depending on the analyte (Supporting Information, Table S1), by transferring 100 µL of the spiked 280 
plasma into a test tube and stopping the degradation process by adding 300 µL of methanol with 0.1% 281 
(v/v) FA (4 °C). Suspensions were vortexed for 15 s and kept at 4 °C for 30 min. After centrifugation 282 
at 14 000 rpm for 15 min, 100 µL of the supernatant was diluted with 100 µL of water in the injection 283 
vial. Samples were stored in the autosampler (4 °C) prior to injection. Analysis was performed on a 284 
Dionex Ultimate 3000 gradient RP-HPLC system using water/ACN/FA (95/5/0.1 v/v/v) and 285 
ACN/water/FA (95/5/0.1 v/v/v) for elution (CORTECS C18+, 2.1 x 150 mm, 2.7 µm column from 286 
Waters, Milford, Massachusetts, USA). For the calculation of the peptide half-life, only points with an 287 
AUC higher than the AUC of the lowest standard were used. The concentrations were calculated by 288 
use of the calibration curve and transferred to a semi-log chart presenting the log concentrations as a 289 
function of time. To study the fragmentation profile, the samples were transferred to the LC-MS 290 
system and the degradation products were identified by analyzing the m/z ratio of all peaks of the 291 
spectrum. 292 
Data analysis and statistical evaluation 293 
Graphical representations and statistical evaluation were carried out with GraphPad Prism software 294 
(San Diego, California, USA). EC50 values were determined by nonlinear regression using sigmoidal 295 
dose-response curve fit. Calculation of the IC50 values was performed as well with sigmoidal dose-296 
response curve fitting (variable slopes). Microsoft® Office Professional 2010 Excel was used for 297 
calculations of the peptide half-life.  298 
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Results and Discussion 299 
Peptide synthesis  300 
The truncated NMU-8 was taken as lead structure for the synthesis of all analogs, since it is a naturally 301 
occurring form of the neuropeptide, of which the C-terminus is considered to be the critical part of the 302 
peptide for receptor activation [3]. All targeted peptides were synthesized by Fmoc-based SPPS on 303 
Rink Amide AM resin (vide supra) using TBTU as coupling reagent. The N-substituted glycines (the 304 
so-called ‘peptoid’ residues) in peptides 31 - 38 were prepared using the solid phase submonomer 305 
method [27]. Amino acids with an unprotected phenol in their side chain (7-OH-Tic, Dmt) were 306 
coupled using DIC/HOBt in order to prevent O-acylation. For these analogs, as well as for the 307 
hydroxyl-containing peptoids, the remaining peptide sequence was assembled using the DIC/HOBt 308 
mediated couplings. No difficulties were observed to couple Fmoc-Leu-OH to the secondary amine of 309 
the peptoid residues. All peptides were purified to greater than 95% purity by RP-HPLC, and their 310 
structure was confirmed by HRMS (Table S2, supporting information). The tritium labeled NMU-8 311 
which was required for the radioligand displacement experiments, was obtained by first iodination of 312 
NMU-8 [29], to Tyr(3’-I)-NMU-8, followed by catalytic reduction with an excess of tritium gas. The 313 
crude [3H]-NMU-8 was purified by RP-HPLC resulting in the radioligand with a radiochemical purity 314 
of more than 98% and with a specific activity of 1.09 TBq/mmol (29.4 Ci/mmol). 315 
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Table 1. Sequences and in vitro activity and affinity of the literature based NMU-8 analogs (first generation) on hNMUR1 and hNMUR2. [double column] 316 
hNMUR1 hNMUR2    Selectivity 
Potency Affinity Potency Affinity IC50 NMUR2/ 
  Sequence EC50 (nM)  Emax (%) IC50 (nM)   EC50 (nM)  Emax (%) IC50 (nM)   IC50 NMUR1 
1 H-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 38.9  100.0 0.78 30.8 100.0 1.7 2 
2 Ac-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 0.51 111.3 0.29 0.71 100.0 2.0 7 
3 H-Tyr-Phe-Leu-Phe-Ala-Pro-Arg-Asn-NH2 709.4 57.1 - 391.0 68.1 - - 
4 Ac-Tyr-Phe-Leu-Phe-Ala-Pro-Arg-Asn-NH2 274.6 61.0 - 242.2 75.5 - - 
5 H-D-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 18.6 71.3 - 34.3 103.7 - - 
6 Ac-D-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 8.1 57.4 - 6.2 99.0 - - 
7 H-Tyr-Phe-Leu-Phe-Arg-D-Pro-Arg-Asn-NH2 3171 73.1 1167 1079 110.7 802.9 0.7 
8 Ac-Tyr-Phe-Leu-Phe-Arg-D-Pro-Arg-Asn-NH2 2271 71.0 844.4 2002 80.9 1365 2 
9 H-Tyr-Phe-D-Leu-Phe-Arg-D-Pro-Arg-Asn-NH2 NA NA 775.5 2495 98.4 6132 8 
10 Ac-Tyr-Phe-D-Leu-Phe-Arg-D-Pro-Arg-Asn-NH2 NA NA 3755 NA NA 1089 0.3 
11 H-Tyr-Phe-Leu-Phe-Arg-Pro-D-Arg-Asn-NH2 683.7 56.6 - 616.1 131.1 - - 
12 Ac-Tyr-Phe-Leu-Phe-Arg-Pro-D-Arg-Asn-NH2 343.4 64.1 - 382.3 138.8 - - 
13 3-cyclohexylpropionyl-Leu-Leu-Dap-Pro-Arg-Asn-NH2 NA NA 4286 3.8 91.9 43.9 0.01 
14 3-cyclohexylpropionyl-Leu-Leu-Dap-D-Pro-Arg-Asn-NH2 NA NA 18320   926.3 100.4 10700   0.6 
 317 
Modifications compared to the native NMU-8 sequence (1) are marked in bold. EC50 values are calculated based on the IP3 SPA data. Emax is the percentage of the maximum 318 
response at 10-5 M compared with the NMU-8 response at the same concentration. IC50 values are calculated based on the competitive binding assay. Receptor selectivity is 319 
expressed as the ratio of the IC50 value for NMUR2 over the IC50 value for NMUR1 of each NMU-analog. NA: not applicable, no agonist activity up to 10-6 M. -: not 320 
determined. 321 
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Biological evaluation of the first set of NMU-analogs 322 
Evaluation of the agonistic activities at the NMURs of the first set of NMU-analogs was performed in 323 
the present study on HEK293 cells transiently expressing hNMUR1 or hNMUR2 using an inositol 324 
triphosphate (IP3) SPA assay. The affinity of a selection of analogs for the NMURs was determined in 325 
these cells using competitive displacement with [3H]-NMU-8 as radioligand. Table 1 shows the results 326 
for the modified peptides (Supporting information, Table S3, for results presented as mean ± SEM).  327 
N-terminal acetylation 328 
It is reported that enzymatic degradation of the NMU-8 peptide mainly occurs via the N-terminus [14]. 329 
With the aim to develop NMU-analogs possessing an increased stability, N-terminal modifications 330 
were introduced in the peptide sequence. Sakura et al. described that acetylation of the N-terminal Tyr1 331 
leads to an increased resistance against proteolysis. Moreover, it has previously been shown that this 332 
modification led to an increase in contractile activity on chicken crop smooth muscle preparations 333 
[14]. In the present study, we evaluated Ac-NMU-8 (2) in an IP3 accumulation assay on HEK293 cells, 334 
an immediate read-out for receptor activation. The introduction of an acetyl group at the N-terminus 335 
(2) led to a more than 40-fold increase in potency on both NMURs (with EC50 values of 0.51 nM and 336 
0.71 nM for NMUR1 and NMUR2, respectively) when compared to the native NMU-8 (1) (EC50 = 337 
38.9 nM for NMUR1 and 30.8 nM for NMUR2). N-terminal acetylation of 1 did not alter the affinity 338 
for the NMURs. Acetylation of the N-terminus was systematically carried out in the current study, to 339 
present both the acetylated and non-acetylated form of all analogs, and led in general to an increase of 340 
the relative activity on both NMURs, when compared to the non-acetylated peptide.  341 
[Ala5]-NMU-8 342 
A previous study by Funes et al. reported a tool for shifting selectivity towards NMUR2 when 343 
replacing Arg5 by an Ala residue [30]. However, in our hands this modification (3) led only to a 344 
slightly increased selectivity for NMUR2 (EC50 for NMUR1= 709.4 nM and EC50 for NMUR2 = 345 
391.0 nM) instead of the 15-fold shift reported by Funes et al. The loss in potency, compared to 346 
NMU-8, came with partial agonism on both NMURs. N-terminal acetylation of this analog (4) 347 
increased the potency for both receptors, although activity remained low, as compared to NMU-8. 348 
However, partial agonists can be of therapeutic importance since they could be regarded as molecules 349 
exerting both agonistic, when low levels of the endogenous ligand is present, and antagonist effects, 350 
when present together with a full agonist competing for the same binding site [31].  351 
Chirality switches 352 
A D-amino acid scan of NMU-8 was performed by Hashimoto et al. and tested on isolated chicken 353 
crop smooth muscle preparations [13]. Inspired by the SAR studies which were performed in ‘the 354 
early days of NMU research’, we decided to synthesize some of these analogs and evaluate them on 355 
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cell cultures expressing the NMURs. [D-Tyr1]-NMU-8 was reported to enhance the contractile activity 356 
in the smooth muscle preparation, presumably due to an increased resistance to aminopeptidase-like 357 
degradation [13]. In our hands, replacing Tyr1 by D-Tyr led to peptide 5, and its acetylated form 6, 358 
with comparable potencies to NMU-8 for NMUR1 and NMUR2, although a decrease of its maximal 359 
effect (Emax, effect at 10-5 M compared with the response of the same concentration of NMU-8) on 360 
NMUR1 was observed (e.g., 57.4 % for 6). However, rather than an increase in potency compared to 361 
the parent peptide, a decreased potency was observed especially when comparing activities of the 362 
acetylated forms 6 versus 2. In the literature, [D-Pro6]-NMU-8 and [D-Leu3,D-Pro6]-NMU-8 were 363 
found to be weak non-competitive antagonists in chicken crop preparations [13]. We included both 364 
molecules and their N-terminal acetylated forms (compounds 7-10) in our study. These ligands indeed 365 
did not show potent agonistic activity in the in vitro cell-based assays. To further investigate if these 366 
molecules could act as antagonists on the NMURs, their ability to compete with radiolabeled agonist, 367 
[3H]-NMU-8, was evaluated. These compounds (7 – 10) all showed a 1000-fold, or even higher, 368 
decrease in affinity for NMUR1. On NMUR2, binding studies revealed a major loss in affinity, 369 
ranging from a 400 to more than 3000-fold decrease. These results demonstrate that these 370 
modifications lead to a loss in affinity and potency of the molecules. To our knowledge, no peptidergic 371 
antagonists for NMUR1 or NMUR2 have been proven to exert activity in vivo until now. This 372 
correlates with the observation that [D-Pro6]-NMU-8 failed to exert antagonistic activity in vivo [32]. 373 
However, a small molecule antagonist for NMUR2, R-PSOP, was reported by Liu et al [33]. 374 
Replacing Arg7 by D-Arg (11, 12) resulted in full agonists with an even higher intrinsic activity than 375 
NMU-8 on NMUR2 (Emax values of 131.1 % and 138.8 % for 11 and 12, respectively), but these 376 
analogs gave way to a decrease in potency on both receptors. However, these molecules still possessed 377 
similar potencies on NMUR1, as compared to the activity on NMUR2, they were only able to partially 378 
activate this receptor. Finally, Takayama et al described a selective NMUR2 receptor agonist, namely 379 
3-cyclohexylpropionyl-Leu-Leu-Dap-Pro-Arg-Asn-NH2 [18], which was resynthesized as compound 380 
13 together with the analog where Pro was replaced by D-Pro (14), in order to verify whether this 381 
could lead to selective NMUR2 receptor antagonism. Also in our hands, analog 13 acted as a selective 382 
NMUR2 agonist with a lower affinity but conserved potency on NMUR2 as compared to NMU-8. The 383 
additional D-amino acid substitution did not give rise to a NMUR2 selective antagonists as compound 384 
14 possessed a weak affinity and in consequence a low activity on both NMURs. 385 
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Table 2. Sequences and in vitro activity and affinity of the novel NMU-8 analogs (second set) for hNMUR1 and hNMUR2. [double column] 386 
 387 
 388 
 389 
 390 
 391 
 392 
 393 
 394 
 395 
 396 
 397 
 
 
Modifications 
compared to 
the native 
NMU-8 
sequence (1) 
are marked 
in bold. 
EC50 values 
are calculated 
based on the 
IP3 SPA 
data. Emax is the 
percentage of the 
maximum response at 10-5 M 413 
compared with the NMU-8 response at the same concentration. IC50 values are calculated based on the competitive binding assay. Receptor selectivity is expressed as the ratio of the IC50 value for NMUR2 over the IC50 value for NMUR1 of each 414 
NMU- analog.415 
hNMUR1 hNMUR2    Selectivity 
Potency Affinity Potency Affinity IC50 NMUR2/ 
  Sequence EC50 (nM)  Emax (%) IC50 (nM)   EC50 (nM)  Emax (%) IC50 (nM)   IC50 NMUR1 
1 H-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 38.9  100.0 0.78  30.8 100.0 1.7  2 
15 H-7-OH-Tic-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 5.5 103.5 0.086 3.5 115.3 21.4 249 
16 Ac-7-OH-Tic-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 5.1 99.3 0.037 13.4 115.8 12.3 332 
17 H-2'Nal-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 65.8 95.1 0.97 4.8 106.1 9.9 10 
18 Ac-2'Nal-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 1.6 90.9 0.88 1.6 83.9 5.6 6 
19 H-Dmt-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 10.4 95.0 0.34 0.83 100.7 4.3 13 
20 Ac-Dmt-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH2 4.0 109.1 0.15 0.70 91.5 2.4 16 
21 H-Tyr-Phe-Leu-7-OH-Tic-Arg-Pro-Arg-Asn-NH2 94.5 94.6 8.6 624.3 109.1 1010 117 
22 Ac-Tyr-Phe-Leu-7-OH-Tic-Arg-Pro-Arg-Asn-NH2 12.3 88.1 1.2 192.6 86.1 330.8 276 
23 H-Tyr-Phe-Leu-1'Nal-Arg-Pro-Arg-Asn-NH2 41.4 101.1 0.31 225.7 109.8 370.5 1195 
24 Ac-Tyr-Phe-Leu-1'Nal-Arg-Pro-Arg-Asn-NH2 4.3 105.3 0.41 246.5 86.4 39.1 95 
25 H-Tyr-Phe-Leu-2'Nal-Arg-Pro-Arg-Asn-NH2 51.0 103.0 0.51 378.0 104.7 424.4 832 
26 Ac-Tyr-Phe-Leu-2'Nal-Arg-Pro-Arg-Asn-NH2 4.2 109.0 0.32 304.2 96.2 195.3 610 
27 H-Tyr-Phe-Leu-Dmt-Arg-Pro-Arg-Asn-NH2 77.9 96.1 1.6 1286 103.4 1649 1031 
28 Ac-Tyr-Phe-Leu-Dmt-Arg-Pro-Arg-Asn-NH2 7.7 104.4 0.36 3675 96.7 1857 5158 
29 H-Tyr-Phe-Leu-Oic-Arg-Pro-Arg-Asn-NH2 184.9 72.2 66.2 472.1 92.0 1546 23 
30 Ac-Tyr-Phe-Leu-Oic-Arg-Pro-Arg-Asn-NH2 93.0 83.1 68.6  1830 92.5 253.4  4 
31 H-Tyr-Phe-Leu-N(Benzyl)Gly-Arg-Pro-Arg-Asn-NH2 1053 73.7 46.3  1103 103.1 1403  30 
32 Ac-Tyr-Phe-Leu-N(Benzyl)Gly-Arg-Pro-Arg-Asn-NH2 172.2 73.6 83.1  1278 85.4 1019  12 
33 H-Tyr-Phe-Leu-N(4-OH-Benzyl)Gly-Arg-Pro-Arg-Asn-NH2 593.7 54.6 173.8  1407 69.4 1961  11 
34 Ac-Tyr-Phe-Leu-N(4-OH-Benzyl)Gly-Arg-Pro-Arg-Asn-NH2 191.7 60.1 27.9  2686 75.4 1813  65 
35 H-Tyr-Phe-Leu-N(Phenethyl)Gly-Arg-Pro-Arg-Asn-NH2 822.7 75.5 30.2  355.7 121.8 261.6  9 
36 Ac-Tyr-Phe-Leu-N(Phenethyl)Gly-Arg-Pro-Arg-Asn-NH2 138.9 83.1 62.9  250.0 99.9 316.1  5 
37 H-Tyr-Phe-Leu-N(4-OH-Phenethyl)Gly-Arg-Pro-Arg-Asn-NH2 574.4 57.6 100.1  382.2 94.3 428.9  4 
38 Ac-Tyr-Phe-Leu-N(4-OH-Phenethyl)Gly-Arg-Pro-Arg-Asn-NH2 216.6 60.6 3.9  339.2 80.7 206.9  53 
39 H-Tyr-Phe-Leu-Phe-Arg-Tic-Arg-Asn-NH2 5496 79.0 162.3  45.5 99.3 13.0  0.08 
40 Ac-Tyr-Phe-Leu-Phe-Arg-Tic-Arg-Asn-NH2 230.0 72.9 54.4  5.4 91.8 11.2  0.2 
41 H-Tyr-Phe-Leu-Phe-Arg-Oic-Arg-Asn-NH2 273.2 106.3 24.3   10.2 90.4 12.7  0.5 
42 Ac-Tyr-Phe-Leu-Phe-Arg-Oic-Arg-Asn-NH2 28.8 95.0 11.2  1.8 84.3 13.9   1 
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 416 
Figure 3. In vitro evaluation of the effect of Tyr1 substitution on receptor activation. IP3 accumulation 417 
assay performed on HEK293 cells, transiently expressing A) NMUR1 or B) NMUR2. C) Structures of 418 
the novel NMU-analogs 15, 16, 17, 18, 19 and 20. Data are shown as mean ± SEM (n=3). [double 419 
column] 420 
Biological evaluation of the second set of NMU-analogs 421 
Substitution of the N-terminal tyrosine residue  422 
To protect the peptides from cleavage by aminopeptidases, the N-terminus of NMU-8 was modified. 423 
Figure 3 gives an overview of the NMU-analogs with modification at the Tyr1 residue and their 424 
activity at NMUR1 and NMUR2. An analog wherein Tyr1 was replaced by 7-OH-Tic was synthesized 425 
together with the N-terminally acetylated peptide, to give compounds 15 and 16. Both molecules 426 
showed a very high, picomolar affinity for NMUR1, which is about ten times better than those of the 427 
parent compounds 1 and 2, whereas their affinity for NMUR2 decreased. In the activity assay, they 428 
were however non-selective, full agonists with a 15 % increase of the maximal effect at NMUR2 429 
(Table 2). When Tyr1 was replaced by 2’-naphtylalanine (2’Nal), a non-selective agonist for the 430 
NMURs (17) with similar affinity and potency as compared to compound 1 was found. The acetylated 431 
analog (18) however, is more potent than NMU-8 at NMUR1 and NMUR2, with a similar activity on 432 
both receptors and a 6-fold higher affinity for NMUR1 (Table 2 and Figure 3). Finally, a substitution 433 
by Dmt resulted in potent, but non-selective, NMUR agonists 19 and 20. They possessed a 434 
subnanomolar affinity for NMUR1, yet an increased potency on NMUR2 was observed.  435 
These modifications of the Tyr residue, namely replacement by 7-OH-Tic, 2’Nal or Dmt, led to the 436 
discovery of potent NMU-analogs. It indicates that the side chain hydroxyl function in this position is 437 
not important for receptor activation. However, an aromatic moiety should be present. Consequently, 438 
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when the N-terminus was acetylated, these analogs became even more potent on both receptors, 439 
presenting all an increased potency compared to NMU-8, with compound 16 as the only exception. It 440 
has an approximately 4-fold lower potency on NMUR2 than the analog with the free amine at the N-441 
terminus (15). However, it was equipotent on this receptor as compared with the native NMU-8 442 
peptide. All compounds (15 – 20) possessed higher affinity for NMUR1 although most molecules lead 443 
to an increased activity on NMUR2. 444 
 445 
Figure 4. In vitro evaluation of the effect of Phe4 substitution on affinity and receptor activation. A) 446 
IP3 accumulation assay performed on HEK293 cells, transiently expressing NMUR1. B) Competitive 447 
binding assay with [3H]-NMU-8 carried out on HEK293 cells, transiently expressing NMUR1. C) 448 
Structures of the novel NMU-analogs 24, 26 and 28.  Data are shown as mean ± SEM (n = 3). [double 449 
column] 450 
Introduction of unnatural amino acids in position 4 451 
Modifications of the Phe residue in position 4 were introduced to prevent the cleavage of the peptide 452 
at the biodegradation site Phe-Arg, which was proposed by Takayama et al. after in vitro stability 453 
assays in rat serum [19]. By replacing Phe4 by 7-OH-Tic, both the analogs with a free amine N-454 
terminus (21) and the acetylated form (22) were agonists on NMUR1. Compound 21 resulted in an 455 
agonist with a minor loss in affinity and potency on this receptor. On the other hand, its acetylated 456 
form (22) possessed an increased affinity and potency, as compared to NMU-8, although a loss of 457 
more than 10 % of the maximal agonist activity was observed (Table 2). On NMUR2, this 458 
modification led to a drop in affinity, and consequently the activity. Moreover, the maximal effect on 459 
NMUR2 decreased with more than 10 % for analog 22. When a bulky aromatic residue, 1’Nal (23) or 460 
2’Nal (25), was introduced in the sequence, full agonists were obtained for NMUR1 with similar 461 
potencies as NMU-8. When these analogs were acetylated at their N-terminus, to give compounds 24 462 
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and 26 respectively, potent agonists were found with a 10-fold higher activity at NMUR1 and an 463 
increased affinity. For these compounds (23 – 26), a loss in affinity and activity for NMUR2 was 464 
found. All potent NMUR1 selective NMU-analogs, obtained by modification of Phe4, are presented in 465 
Figure 4. When a bulky Tyr-analog was introduced in the position of Phe4 (i.e. by replacing Phe with 466 
Dmt to give 27), a NMUR1-selective agonist with a slightly diminished potency (EC50= 77.9 nM), as 467 
compared to NMU-8, was again obtained. The acetylated analog (28) showed a higher potency and 468 
affinity for NMUR1 (Figure 4). A last modification which was introduced in this position consisted of 469 
the replacement of Phe by octahydroindolecarboxylic acid (Oic), a residue that can be regarded as a 470 
saturated and constrained Phe surrogate. Unfortunately, both compounds 29 and 30, were 471 
characterized by a lower potency and affinity on both NMURs as compared to NMU-8.  472 
Importantly, these results reveal that the modification of Phe in position 4 can serve as a tool to obtain 473 
NMU-analogs with an increased selectivity for NMUR1. Moreover, it shows that a hydroxyl function 474 
in the side chain of Phe is tolerated since the NMUR1 activation is unaltered when Dmt was 475 
introduced. However, when Phe is replaced by 7-OH-Tic, a decrease in affinity for NMUR1 was 476 
found. This could be explained by the fact that an unfavorable conformational constraint is imposed, 477 
and hence that the side chain is forced in a less favorable position for binding to the NMURs [34]. 478 
Remarkably, this loss in affinity could be restored by the introduction of an acetyl group at the N-479 
terminus. Moreover, when Phe is replaced by Oic, the potency diminished even more due to a loss in 480 
affinity for the NMURs. 481 
N-substituted glycines in position 4 482 
A series of N-substituted glycines, the so-called ‘peptoid’ residues, was introduced in the NMU-8 483 
sequence to mimic the aromatic character of Phe, while aiming to protect the degradation site Phe-Arg 484 
by using another strategy than for the analogs of the previous section. Moreover, a shift of the side 485 
chain from the α-carbon to the nitrogen in neurotensin(8-13) has been shown to shift the receptor 486 
selectivity from NTSR1 to NTSR2 [35]. Hence, benzyl, 4-hydroxy-benzyl, phenethyl and 4-hydroxy-487 
phenethyl moieties were inserted instead of Phe4 in order to verify whether selectivity could be 488 
impacted. However, all NMU-analogs with a N-substituted Gly instead of Phe at position 4 489 
(compounds 31 – 38) resulted in weak agonists with a loss in potency and a lower Emax compared to 490 
our endogenous lead peptide NMU-8. Moreover, a decreased affinity for both NMURs was observed 491 
as well. It can be speculated that the backbone amide is necessary for receptor binding and activation. 492 
Another explanation for the loss of affinity and activity could be that the side chain is not aligned into 493 
the right position to favor binding and, subsequently, to exert an effect on the NMURs. Of note, to 494 
compensate for such an unfavorable shift of the side chains, the homologated phenethyl and 4-495 
hydroxy-phenethyl ‘side chains’ were applied, even though unsuccessfully. 496 
Substitution of the proline residue 497 
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The naturally constrained Pro6 residue was replaced by the conformationally constrained 1,2,3,4-498 
tetrahydroisoquinoline-3-carboxylic acid (Tic) residue. This bridged residue led to poor partial 499 
NMUR1 agonists (39 and 40), which possessed a decreased receptor affinity as compared to NMU-8. 500 
Although these analogs had a lower affinity for NMUR2 than compound 1, the non-acetylated peptide 501 
was able to fully activate NMUR2 with only a 4.5 fold higher EC50 value. Moreover, compound 40 502 
was found to have a 2-fold higher potency at NMUR2, but it was not able to fully activate the receptor 503 
(Emax = 91.8 %). Similarly to the insertion of Tic at this position, replacement of Pro by Oic led to a 504 
potent agonist (41) on NMUR2, even though it was already stated in literature that the Pro-Arg-Asn-505 
NH2 segment is critical for receptor activation [18]. Moreover, when this peptide was N-terminally 506 
acetylated (42), the NMU-8 potency was exceeded. On NMUR1, the substitution of Pro by Oic led to 507 
a full agonist with a 7-fold decrease in potency. However, when an acetylation was introduced at the 508 
N-terminus, the NMU-8 potency was restored. Both compounds 41 and 42 possessed a decreased 509 
affinity for the NMURs. Interestingly, modifications in this, previously described, critical part of the 510 
NMU-8 sequence show that other cyclic amino acids are tolerated in this region of the peptide. 511 
Substitution of Pro gave rise to molecules with an increased NMUR2 selectivity and high potency at 512 
this receptor subtype, which makes it an attractive tool to further develop receptor subtype selective 513 
analogs.  514 
In vitro plasma stability 515 
To evaluate the effect of the introduced modifications on the proteolytic stability of the NMU-analogs, 516 
in vitro degradation studies in human plasma at 37 °C were performed on a selection of the novel 517 
peptides. The percentage of the intact NMU-analog was measured over time by HPLC-UV analysis 518 
(Figure 5). Afterwards the samples were analyzed by means of MS and degradation profiles were 519 
studied (Figure 6). Depending on the stability of the peptide, samples were taken at different time 520 
points (Table S1).  521 
NMU-8 (1) was characterized by a short half-life of only 4.3 ± 0.2 min. It was rapidly degraded at its 522 
unprotected N-terminus where Tyr1 was cleaved from the sequence. Since acetylation of the N-523 
terminal amine was systematically performed on all NMU-analogs described in this study, the 524 
resistance to biological degradation of compound 2 was evaluated next. When an acetyl group was 525 
introduced at the N-terminus of the NMU-8 sequence, a more than 25-fold increase of the half-life 526 
(117.8 ± 0.7 min) was observed. The prior cleavage site Tyr1-Phe2 was protected by this N-terminal 527 
modification and degradation took place by cleavage of the peptide between the Phe2 and Leu3 528 
residues. Substitutions of the Tyr residue did not lead to a further increase of the enzymatic stability 529 
with calculated half-lifes of 109.8 ± 3.1 min, 128.8 ± 1.7 min and 154.5 ± 10.2 min for compounds 16, 530 
18 and 20, respectively.  531 
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 532 
Figure 5. Percentage of recovery of NMU-analogs in human plasma incubated at 37 °C. The 533 
experiments were performed in triplicate and the results are presented as mean ± SEM (n = 3). [single 534 
column Figure] 535 
Although introduction of a modified amino acid in position 1 gave rise to molecules with a similar 536 
half-life compared to Ac-NMU-8 (2), it was observed that the major cleavage site of compound 16 537 
was situated in the middle of the sequence, between Phe4 and Arg5. This position was proposed earlier 538 
to be an important biodegradation site [19]. Next, the peptide was cleaved further at the same position 539 
as described for compound 2, namely after Phe2. The NMU-analog 18 was characterized by the same 540 
major cleavage site as for 16, but the introduction of 2’Nal in the sequence led to stabilization of the 541 
labile Phe2-Leu3 segment. In a smaller extent the peptide was cleaved between Pro6 and Arg7. When an 542 
unnatural amino acid was introduced in position 4, e.g., Dmt instead of Phe for compound 28, a 2-fold 543 
increase of the half-life in human plasma was found, as compared to Ac-NMU-8 2 and an almost 60-544 
fold increase when it was compared to the native peptide 1. The major biodegradation site remained in 545 
the middle of the sequence, namely at Dmt4-Arg5, but the cleavage was significantly hampered via the 546 
replacement of Phe by Dmt at this position. As expected, the introduction of the ‘peptoid’ residues at 547 
Phe4 resulted into NMU-analogs with an increased resistance against proteolytic degradation. The 548 
stability assay revealed that compound 32 had a half-life of 837.4 ± 27.8 min (or 14.6 ± 0.8 h) in 549 
human plasma. When Phe4 was replaced by N(4-OH-phenethyl)Gly (38), it was even higher, namely 550 
1096.1 ± 56.1 min (18.3 ± 0.9 h). Moreover, the switch of Phe4 by N-substituted glycines changed the 551 
biodegradation profile. The major cleavage site moved towards the C-terminus of the peptide, more 552 
precisely between Arg7 and Asn8. A last subset of modifications which was used in this study, is the 553 
substitution of the Pro residue. When it was replaced by Oic to give 42, a molecule with a high 554 
resistance to enzymatic degradation was found. The half-life of analog 42 in human plasma was 555 
1426.1 ± 67.4 min or 23.8 ± 1.1h. The major degradation site for this analog was as well located 556 
between Arg7-Asn8. When considering the activity profile of compound 42, and taking its proteolytic 557 
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stability into account, this analog can be considered as a good lead for the development of potent and 558 
stable NMUR2 agonists.  559 
 560 
Figure 6. Cleavage sites of the NMU analogs after incubation in human plasma at 37 °C. The major 561 
biodegradation sites are indicated with dotted lines of which the numbers represent the order of 562 
cleavage.  563 
Previously, the stability of some NMU-based molecules was already reported in literature. Lipidation 564 
of NMU-8 markedly increased its half-life in mouse plasma as compared to hNMU [21]. Moreover, 565 
when the effect on proteolytic stability was studied of molecules without high molecular carriers, 566 
improved resistance towards degradation was observed as well. The selective NMUR1 agonist, 2-567 
thienylacetyl-Trp-(αMe)Trp-Arg-Pro-Arg-Asn-NH2, which was recently described by Takayama et al, 568 
possessed an improved in vitro serum stability with a half-life of approximately 180 min [20]. Here, 569 
we discovered molecules with plasma half-lifes up to 23 h. The potent NMUR1 agonist, compound 28, 570 
possessed a half-life of 253.5 ± 6.0 min. In the present study, human plasma was used for the 571 
determination of the biodegradation profiles. This does not allow direct comparison with the metabolic 572 
stability of 2-thienylacetyl-Trp-(αMe)Trp-Arg-Pro-Arg-Asn-NH2, which was studied in serum. 573 
Moreover, it was reported that the preferential biodegradation site of this NMUR1 selective agonist 574 
was located between the Arg and Asn residues and that the key enzyme, responsible for this cleavage, 575 
was found to be thrombin [20, 36]. The present study is giving more accurate information when 576 
compared to studies where experiments were performed with 25% rat or human serum [19, 20], since 577 
in plasma the inactive prothrombin is present, giving a closer representation of physiological 578 
conditions. 579 
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Conclusions 582 
A novel set of NMU-analogs was developed and characterized in vitro. The core sequence of the 583 
NMU-peptide, more precisely NMU-8, was taken as lead molecule for the SAR-study. Potent agonists 584 
(compounds 15 – 20), with equal activity on both NMURs, were obtained when the Tyr1 residue was 585 
modified, with affinities and activities in the nM range. Moreover, these peptides turned out to have an 586 
elevated resistance against proteolytic degradation, resulting in molecules with an increased half-life in 587 
human plasma. We demonstrated that substitution of Phe4 could serve as a tool for NMUR1 selectivity 588 
and improved plasma stability, which resulted in the discovery of potent NMU-analogs with increased 589 
NMUR1 selectivity and enhanced stability in human plasma, more precisely analog 24, 26 and 28. By 590 
synthesizing peptides with a modified Pro6 residue, an increased potency on NMUR2 was observed.  591 
Moreover, a remarkable effect on the enzymatic stability was found, going from 4 min for NMU-8 to 592 
approximately 24 h for 42. By evaluating the effect of D-amino acid substitution on receptor affinity, 593 
we demonstrated that the previously reported tool for antagonism led to a loss in affinity rather than 594 
antagonism. We believe that this novel set of NMU-analogs can have potential in the development of 595 
receptor selective NMU-based peptides with improved proteolytic stability.    596 
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• Insertion of unnatural amino acids in NMU-8 leads to stable and selective ligands 
• Potent NMUR ligands can be found by substitution of the Tyr1 residue of NMU-8 
• NMUR1 selectivity can be achieved by modification of Phe in position 4 
• Replacement of the Pro6 residue shifts the selectivity towards NMUR2  
• Biodegradation profiles are studied in human plasma 
